Market Place
Sourcing Support
TG Therapeutics Backpedals on BLA for Lymphoma, Leukemia Treatment
16 Apr 2022 //
BIOSPACE
FDA investigate possible increased risk of death with lymphoma medicine
09 Feb 2022 //
PHARMAFILE
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold
28 Jan 2022 //
YAHOO FINANCE
TG Therapeutics Announces Publication of Results Integrated Safety of UKONIQ®
23 Sep 2021 //
GLOBENEWSWIRE
TG seeks US FDA approval for Ublituximab in combo with Umbralisib
02 Dec 2020 //
PHARMABIZ
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib
02 Dec 2020 //
TGTHERAPEUTICS
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib
01 Dec 2020 //
GLOBENEWSWIRE
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib
13 Aug 2020 //
PRESS RELEASE
TG Therapeutics Completes Rolling Submission of NDA to the USFDA for Umbralisib
17 Jun 2020 //
PRESS RELEASE
TG Therapeutics Announces Data Presentations at the 25th (EHA) Annual Congress
12 Jun 2020 //
PRESS RELEASE
Another sparse round of NASH data; TG raises $60M after PhIII success
06 May 2020 //
ENDPTS
TG Therapeutics Receives Orphan Drug Designation for Umbralisib
05 Mar 2020 //
PRESS RELEASE
Umbralisib Developer Seeks FDA Approval In Marginal Zone Lymphoma
16 Jan 2020 //
TARGETED ONCOLOGY
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2bstudy
28 Oct 2019 //
BIOSPACE
TG Therapeutics Announces Final Phase 2 MS Data Accepted
26 Sep 2018 //
GLOBENEWSWIRE
TG stock sinks after setback to blood cancer trial
25 Sep 2018 //
FIERCE BIOTECH
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib
18 Jun 2018 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.